Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Advances in Traditional Medicine ; 23(1):59-84, 2023.
Article in English | EMBASE | ID: covidwho-2259382

ABSTRACT

Since the outbreak in December 2019, in Wuhan (China) of COVID-19, approved drugs are still lacking and the world is seeking effective treatment. The purpose of this article is to review the medicinal plants with potential to be used as complementary therapies against COVID-19. Bibliographic information was searched in several databases (Google Scholar, PubMed, Scopus, ScienceDirect, PROTA, ResearchGate and GLOBEinMED), to retrieve relevant papers on (1) plants used to manage common symptoms of COVID-19, (2) plant secondary metabolites with confirmed inhibitory effects on COVID-19 and (3) plants exhibiting pharmacological activities of relevance for COVID-19 management. A total of 230 species was recorded as potential source of ingredients for the fight against the 2019 novel corona virus. Of these species, 30 contain confirmed antiCOVID-19 secondary metabolites, 90 are used traditionally to manage at least 3 common symptoms of COVID-19, 10 have immunostimulant activity, 52 have anti-inflamatory activity, 14 have antiviral properties and 78 species are documented as used to treat malaria. A PCA analysis showing cluster formatting among the recorded species indicates 4 groups of species and an array of possibility of using individual species or a combination of species for their complementary effects. The authors argue that Cameroonian medicinal plants can be of potential contribution to the fight against COVID-19. Further applied research is needed to provide more scientific evidence for their efficacy, to establish standard formulations and clinical studies as part of efforts to develop therapies for COVID-19.Copyright © 2021, Institute of Korean Medicine, Kyung Hee University.

2.
Journal of Pharmaceutical Negative Results ; 13:254-264, 2022.
Article in English | Web of Science | ID: covidwho-2072518

ABSTRACT

Drug repurposing, also known as repositioning, is a technique in which existing drugs are repurposed to treat emerging and complex diseases like COVID-19. Because of the potential for shorter development timelines and lower overall costs, drug repurposing has emerged as a promising strategy. In the significant data era, artificial intelligence (AI) and network medicine provide cutting-edge information science applications to define disease, medicine, therapeutics, and identify targets with the smallest error. We present guidelines for using AI to accelerate drug repurposing or repositioning, for which AI approaches are formidable and required in this Review. We discuss how to use AI models in precision medicine, such as how AI models can accelerate COVID-19 drug repurposing. Rapidly developing, powerful, and innovative AI and network medicine technologies can help to accelerate therapeutic development. This Review makes a strong case for using artificial intelligence-powered assistive tools to reptupose medications for human disease, including during the COVID-19 pandemic.

3.
Environ Sci Pollut Res Int ; 29(39): 58628-58647, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1919917

ABSTRACT

This current study review provides a brief review of a natural bee product known as propolis and its relevance toward combating SARS-CoV viruses. Propolis has been utilized in medicinal products for centuries due to its excellent biological properties. These include anti-oxidant, immunomodulatory, anti-inflammatory, anti-viral, anti-fungal, and bactericidal activities. Furthermore, studies on molecular simulations show that flavonoids in propolis may reduce viral replication. While further research is needed to validate this theory, it has been observed that COVID-19 patients receiving propolis show earlier viral clearance, enhanced symptom recovery, quicker discharge from hospitals, and a reduced mortality rate relative to other patients. As a result, it appears that propolis could probably be useful in the treatment of SARS-CoV-2-infected patients. Therefore, this review sought to explore the natural properties of propolis and further evaluated past studies that investigated propolis as an alternative product for the treatment of COVID-19 symptoms. In addition, the review also highlights the possible mode of propolis action as well as molecular simulations of propolis compounds that may interact with the SARS-CoV-2 virus. The activity of propolis compounds in decreasing the impact of COVID-19-related comorbidities, the possible roles of such compounds as COVID-19 vaccine adjuvants, and the use of nutraceuticals in COVID-19 treatment, instead of pharmaceuticals, has also been discussed.


Subject(s)
Biological Products , COVID-19 Drug Treatment , Propolis , Anti-Inflammatory Agents , Antiviral Agents/pharmacology , COVID-19 Vaccines , Humans , Propolis/pharmacology , SARS-CoV-2
4.
Phytochem Rev ; 19(2): 449-489, 2020.
Article in English | MEDLINE | ID: covidwho-116645

ABSTRACT

ABSTRACT: Stephania tetrandra S. Moore (S. tetrandra) is distributed widely in tropical and subtropical regions of Asia and Africa. The root of this plant is known in Chinese as "Fen Fang Ji". It is commonly used in traditional Chinese medicine to treat arthralgia caused by rheumatism, wet beriberi, dysuria, eczema and inflamed sores. Although promising reports have been published on the various chemical constituents and activities of S. tetrandra, no review comprehensively summarizes its traditional uses, phytochemistry, pharmacology and toxicology. Therefore, the review aims to provide a critical and comprehensive evaluation of the traditional use, phytochemistry, pharmacological properties, pharmacokinetics and toxicology of S. tetrandra in China, and meaningful guidelines for future investigations.

SELECTION OF CITATIONS
SEARCH DETAIL